Autopsy report · NCT00619229

Alprostadil in Maculopathy Study (AIMS)

“Interim Analysis: Optimization of study design required.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months after it had already started.
• Ran for about 3 years 7 months before it stopped.
• 37 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

UCB Pharma

Sponsor type

Industry

Conditions

Macular Degeneration

Interventions

Alprostadil (prostaglandin E1); Placebo

Participants

37

Sites

6

Countries

Germany

Trials that died the same way

• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (81% match in meaning)
• Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
  “study paused for interim analysis” (74% match in meaning)
• RCT of Mobile Apps & FitBit v. Usual Care
  “Study is paused for interim analysis.” (73% match in meaning)
• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
  “Interim analysis determined the study did not meet criteria to proceed” (72% match in meaning)
• Moxonidine in Patients Undergoing Vascular Surgery
  “Study was stopped after pre-definied interim analysis because of no effects” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.